This NVDIA cluster Greg is touting is a $20M a year dud and a wasted shiny toy created just for him. It is amazing that BMS LT lets Greg buy this expensive waste while so many other important areas are forced to cut to the bone. The only beneficiaries are Greg with his so called thought leader posts to showcase in LinkedIn and NVDIA. You have to understand the context that BMS Research has no history of developing successful new medicines. All we do is buy late stage assets, get the regulatory approvals and commercialize them (e.g. COBENFY, OPDIVO, CAMZYOS, Reblozyl, Breyanzi all through acquisitions, in fact most of the products in the growth portfolio). Only exception is Sotyktu and you all know what a disaster this is turning out to be. The way Greg talks makes you think that we will have so many new medicines churning out through the Research function using this expensive toy. This is a joke. Bill Mayo deservedly takes the fall, but will the BMS LT call out Greg on his wasteful spending that only enhances his profile?